Skip to content

Infectious and non-infectious lung disease risk increased for those with HIV

Treatment with tenofovir associated with more bone loss than abacavir, but long-term consequences unclear

5.25 million receiving ARVs by end of 2009

HIV treatment is costly, especially for the sickest patients

Image: Africa Studio/Shutterstock.com

High long-term economic costs associated with late HIV diagnosis

US CDC finds 19 percent HIV prevalence among MSM in 21-city survey

FTC therapy reduces risk of important resistance mutation

Early warning indicators for drug resistance in resource-limited settings piloted in Namibia

Darunavir/ritonavir as effective in women as men